Study Review – Durable treatment response and improved survival with long-term ruxolitinib

This review is a summary of an individual study; Durable treatment response and improved survival with long-term ruxolitinib in patients with intermediate-2 or high-risk myelofibrosis study. This review summarises and discusses the final 5-year results of the randomised, double-blind, placebo-controlled phase 3 COMFORT-I trial conducted by Verstovsek et al, 2017.

Independent commentary is provided by Dr David Ross, a Consultant Haematologist in SA Pathology with clinical appointments at the Royal Adelaide Hospital and Flinders Medical Centre in Adelaide, Australia.
 

Please login below to download this issue (PDF)

Subscribe